Preclinical Application of CEST MRI to Detect Early and Regional Tumor Response to Local Brain Tumor Treatment
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Related Research Unit(s)
Detail(s)
Original language | English |
---|---|
Article number | 101 |
Journal / Publication | Pharmaceutics |
Volume | 16 |
Issue number | 1 |
Online published | 12 Jan 2024 |
Publication status | Published - 2024 |
Link(s)
DOI | DOI |
---|---|
Attachment(s) | Documents
Publisher's Copyright Statement
|
Link to Scopus | https://www.scopus.com/record/display.uri?eid=2-s2.0-85183154364&origin=recordpage |
Permanent Link | https://scholars.cityu.edu.hk/en/publications/publication(17819291-9bca-41c4-91be-b932bf5ef531).html |
Abstract
Treating glioblastoma and monitoring treatment response non-invasively remain challenging. Here, we developed a robust approach using a drug-loaded liposomal hydrogel that is mechanically compatible with the brain, and, simultaneously, we successfully monitored early tumor response using Chemical Exchange Saturation Transfer (CEST) MRI. This CEST-detectable liposomal hydrogel was optimized based on a sustainable drug release and a soft hydrogel for the brain tumor, which is unfavorable for tumor cell proliferation. After injecting the hydrogel next to the tumor, three distinctive CEST contrasts enabled the monitoring of tumor response and drug release longitudinally at 3T. As a result, a continuous tumor volume decrease was observed in the treatment group along with a significant decrease in CEST contrasts relating to the tumor response at 3.5 ppm (Amide Proton Transfer; APT) and at −3.5 ppm (relayed Nuclear Overhauser Effect; rNOE) when compared to the control group (p < 0.05). Interestingly, the molecular change at 3.5 ppm on day 3 (p < 0.05) was found to be prior to the significant decrease in tumor volume on day 5. An APT signal also showed a strong correlation with the number of proliferating cells in the tumors. This demonstrated that APT detected a distinctive decrease in mobile proteins and peptides in tumors before the change in tumor morphology. Moreover, the APT signal showed a regional response to the treatment, associated with proliferating and apoptotic cells, which allowed an in-depth evaluation and prediction of the tumor treatment response. This newly developed liposomal hydrogel allows image-guided brain tumor treatment to address clinical needs using CEST MRI.
© 2024 by the authors.
© 2024 by the authors.
Research Area(s)
- glioblastoma, CEST MRI, liposome, hydrogel, treatment
Citation Format(s)
Preclinical Application of CEST MRI to Detect Early and Regional Tumor Response to Local Brain Tumor Treatment. / Park, Se-Weon; Lai, Joseph H. C.; Han, Xiongqi et al.
In: Pharmaceutics, Vol. 16, No. 1, 101, 2024.
In: Pharmaceutics, Vol. 16, No. 1, 101, 2024.
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Download Statistics
No data available